Butyrate, PKM2, and the MYB–HDAC2–FOXA2 Differentiation Axis: Placing the Cho Cancer-Reversion Result in the Context of Prior Short-Chain Fatty Acid Chemistry

Abstract

Hypothesis commentary linking the Cho et al. cancer-reversion result ""Control of Cellular Differentiation Trajectories for Cancer Reversion" (MYB, HDAC2, FOXA2) toprior butyrate, HDAC, c-Myb, PKM2, and FOXA2 literature, with inferences from the author’s 2022–2024 posts labeled as such. The author acknowledges the use of Grok (SpaceXAI) for assistance with organization, structural editing, clarity improvements, and incorporation of relevant background. All conceptual content, arguments, and final responsibility for the work remain with the author. Not peer reviewed. Not clinical advice.